Skip to main content
. 2016 Jun 24;11(6):e0158242. doi: 10.1371/journal.pone.0158242

Fig 1. Cumulative incidence function estimates from competing risks data for GVHD and relapse.

Fig 1

Cumulative incidences (vertical reference lines) of aGVHD grade II-IV (at day 100 post-transplant, left panel), cGVHD needing systemic therapy (middle panel) and relapse (at 2 years post-transplant, right panel) are presented across [A] discovery, [B] validation and [C] combined cohorts. Gray’s method of cumulative incidence function estimation for competing risks data revealed significantly higher incidences of cGVHD when KIR genotype mismatched donors were used (p-values <0.05 at the end of follow-up).